SCHEMBL2469520

SCHEMBL2469520

CC(C)(C)OC(=O)N1Cc2cc(C3(Cl)CCC(Oc4ccncn4)CC3)ccc2-n2cnnc2C1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 8/20 0.35
PDE4A P27815 2/20 0.35
PDE4B Q07343 2/20 0.35
PDE4C Q08493 2/20 0.35
PDE4D Q08499 2/20 0.35
AVPR1A P37288 2/20 0.34
OXTR P30559 1/20 0.32
DDB1 Q16531 1/20 0.32
CRBN Q96SW2 1/20 0.32
DGAT1 O75907 1/20 0.32
NAMPT P43490 4/20 0.31
CACNB4 O00305 1/20 0.31
CACNA1A O00555 1/20 0.31
CACNA1G O43497 1/20 0.31
CACNG3 O60359 1/20 0.31
CACNA1F O60840 1/20 0.31
CACNA1H O95180 1/20 0.31
CACNB3 P54284 1/20 0.31
CACNA2D1 P54289 1/20 0.31
CACNG7 P62955 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2473414 0.91 AVPR1A (0.38) AVPR1A
SCHEMBL2473757 0.90 GPR119 (0.34) GPR119PDE4APDE4BPDE4CPDE4D
SCHEMBL2476334 0.88 GPR119 (0.37) GPR119AVPR1AOXTRDDB1CRBN
SCHEMBL2469541 0.88 GPR119 (0.34) GPR119PDE4APDE4BPDE4CPDE4D
SCHEMBL2469674 0.88 PDE4A (0.34) GPR119PDE4APDE4BPDE4CPDE4D
SCHEMBL2473420 0.85 CACNB4 (0.34) GPR119PDE4APDE4BPDE4CPDE4D
SCHEMBL2336887 0.85 PDE4B (0.36) GPR119PDE4APDE4BPDE4CPDE4D
SCHEMBL2336519 0.84 DDB1 (0.35) GPR119PDE4APDE4BPDE4CPDE4D
SCHEMBL2340272 0.84 DDB1 (0.35) GPR119PDE4APDE4BPDE4CPDE4D
SCHEMBL2337016 0.84 DDB1 (0.35) GPR119PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3035939-A1 V1A ANTAGONISTS TO TREAT PHASE SHIFT SLEEP DISORDERS F. Hoffmann-La Roche AG (CH) 2016-06-29 EP claimed
WO-2015024819-A1 V1A ANTAGONISTS TO TREAT PHASE SHIFT SLEEP DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2015-02-26 WO claimed
EP-3035939-A1 V1A ANTAGONISTS TO TREAT PHASE SHIFT SLEEP DISORDERS F. Hoffmann-La Roche AG (CH) 2016-06-29 EP disclosed
WO-2015024819-A1 V1A ANTAGONISTS TO TREAT PHASE SHIFT SLEEP DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2015-02-26 WO disclosed
EP-2370441-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN VIA RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2011-10-05 EP disclosed
WO-2010060836-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN VIA RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-06-03 WO disclosed